US4710380A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of autoimmune disorders with immunoamplifiers
Assignee: AHG LLC
•
Filing: 1986-04-04
•
Granted: 1987-12-01
•
Expires: 2006-04-04
Abstract
Abstract Therapeutic methods for treatment of rheumatoid arthritis, lupis, Type I diabetes, and other autoimmune disorders are described wherein amplifiers of the immune system response are administered to the subject. Instead of further increasing the hyperactive immune response, however, administering the amplifiers has the effect of reducing the excessive immune responsiveness. Compositions for such administration are also described.
Inventors
- 👤 A. Arthur Gottlieb
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 05:48
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/05; A61K35/00; A61K35/12; A61K35/14; A61K35/15; A61K38/06; Y; Y10; Y10S; Y10S424/00; Y10S424/81
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
38 words
A method of treating human or mammalian subjects for disorders characterized by hyperactive immune response, comprising the administration to said subject of an effective dosage amount of an amplifier of the immune system in a pharmaceutically acceptable carrier.
Claim 2
Independent Claim
38 words
A method of treating human or mammalian subjects for disorders characterized by hyperactive immune response, comprising the administration to said subject of an effective dosage amount of an amplifier of the immune system in a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein said disorder is an autoimmune disorder.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein said subject is human.
Claim 5
Dependent Claim
11 words
The method of claim 3 wherein said disorder is rheumatoid arthritis.
Claim 6
Dependent Claim
10 words
The method of claim 3 wherein said disorder is lupus.
Claim 7
Dependent Claim
11 words
The method of claim 3 wherein said disorder is multiple sclerosis.
Claim 8
Dependent Claim
11 words
The method of claim 3 where said disorder is myasthenia gravis.
Claim 9
Dependent Claim
13 words
The method of claim 3 where said disorder is diabetes mellitus (type 1).
Claim 10
Dependent Claim
17 words
The method of claim 3 wherein said dosage amount is titrated by assaying the subject's immune response.
Claim 11
Dependent Claim
16 words
The method of claim 3 wherein said dosage amount is one in the nonparadoxical dosage range.
Claim 12
Dependent Claim
43 words
The method of claim 3 wherein said dosage amount is approximately 10 5 to 10 8 times the amount of said amplifier found to produce a maximal delayed type hypersensitivity response to antigen in a skin test, and said administration is approximately biweekly.
Claim 13
Dependent Claim
40 words
The method of claim 11 wherein said dosage amount is approximately 3×10 6 times the amount of said amplifier found to produce a maximal delayed type hypersensitivity response to antigen in a skin test, and said administration is approximatley biweekly.
Claim 14
Dependent Claim
10 words
The method of claim 1 wherein said amplifier is TGG.
Claim 15
Dependent Claim
11 words
The method of claim 3 wherein said amplifier is Amplifier Beta.
Claim 16
Dependent Claim
11 words
The method of claim 3 wherein said amplifier is Amplifier Zeta-2.
Claim 17
Dependent Claim
65 words
As an article of manufacture, an effective biweekly dosage amount of an amplifier of the immune system for the treatment of an autoimmune disorder, said dosage amount being in a pharmaceutically acceptable carrier, and said dosage amount being approximately 10 5 to 10 8 times the amount of said amplifier found to produce a maximal delayed type hypersensitivity response to antigen in a skin test.
Claim 18
Dependent Claim
65 words
As an article of manufacture, an effective biweekly dosage amount of an amplifier of the immune system for the treatment of an autoimmune disorder, said dosage amount being in a pharmaceutically acceptable carrier, and said dosage amount being approximately 10 5 to 10 8 times the amount of said amplifier found to produce a maximal delayed type hypersensitivity response to antigen in a skin test.
Claim 19
Dependent Claim
36 words
The article of manufacture of claim 16 wherein said dosage amount is approximately 3×10 6 times the amount of said amplifier found to produce a maximal delayed type hypersensitivity response to antigen in a skin test.
Claim 20
Independent Claim
25 words
A method of treating a patient for rheumatoid arthritis comprising administering to said patient, biweekly, the quantity of Amplifier Beta derived from approximately 400,000 leukocytes.
Claim 21
Independent Claim
25 words
A method of treating a patient for rheumatoid arthritis comprising administering to said patient, biweekly, the quantity of Amplifier Beta derived from approximately 400,000 leukocytes.
References Cited (Backward Citations)
US4468379A
Cited
US4616079A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-11-30 | 1991-06-01 | 1991-12-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-11-30 | 1995-06-01 | 1995-12-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-11-30 | 1999-06-01 | 1999-12-01 | $7700.00 | Window Closed / Lapsed |